Inventiva S.A. ADR (IVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IVA POWR Grades
- Sentiment is the dimension where IVA ranks best; there it ranks ahead of 92.27% of US stocks.
- The strongest trend for IVA is in Momentum, which has been heading down over the past 26 weeks.
- IVA's current lowest rank is in the Momentum metric (where it is better than 9.78% of US stocks).
IVA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for IVA is 0.05 -- better than just 10.65% of US stocks.
- IVA's went public 1.05 years ago, making it older than merely 0.58% of listed US stocks we're tracking.
- With a price/sales ratio of 85.24, Inventiva SA has a higher such ratio than 96.28% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Inventiva SA are MUX, TURN, SYTA, VJET, and OPGN.
- IVA's SEC filings can be seen here. And to visit Inventiva SA's official web site, go to www.inventivapharma.com.
IVA Stock Price Chart Interactive Chart >
IVA Price/Volume Stats
| Current price | $13.63 | 52-week high | $19.06 |
| Prev. close | $13.50 | 52-week low | $10.52 |
| Day low | $13.50 | Volume | 1,904 |
| Day high | $13.63 | Avg. volume | 20,666 |
| 50-day MA | $12.92 | Dividend yield | N/A |
| 200-day MA | $14.02 | Market Cap | 526.53M |
Inventiva S.A. ADR (IVA) Company Bio
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Latest IVA News From Around the Web
Below are the latest news stories about Inventiva SA that investors may wish to consider to help them evaluate IVA as an investment opportunity.
Inventiva’s 2021 First-Half Financial Results PresentationDaix (France), September 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that its management team will host a webcast to present the Company’s first-half financial results for 2021 on Tuesday, September 21, 2021. Inventiva’s 2021 f |
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASHActivation of first clinical sites and start of patient screeningThe two-part NATiV3 Phase III clinical trial will evaluate the long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic NASH and F2/F3 stage of liver fibrosisThe primary endpoint of the trial’s part 1 will evaluate the response to the treatment defined by both resolution of NASH and fibrosis improvement of at least one stagePublication of topline results of part 1 of the trial is expected for H2 2024 Based |
Inventiva announces participation at several investor conferences in September 2021Daix (France), August 30, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company’s leadership will participate in four upcoming investor conferences in September 2021. The event details are as follows: Conference n°1: KBCs Li |
Inventiva announces the implementation of an At-The-Market program in the United StatesDaix (France), August 2, 2021 (GLOBE NEWSWIRE) – Inventiva S.A. (NASDAQ: IVA – EURONEXT PARIS: IVA) (the “Company”), a clinical-stage biotechnological company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the implementation of an At-The-Market (“ATM”) program allowing the Company to issue and sell, including with unsolicited investors |
Inventiva Reports First-Half of 2021 Financial InformationCash and cash equivalents at €93.6 m as of June 30, 2021Revenues of €0.2 m in H1 2021 Daix (France), July 28, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of June 30, 2021 and its revenues for the first half of 2 |
IVA Price Returns
| 1-mo | 20.46% |
| 3-mo | -6.19% |
| 6-mo | 8.61% |
| 1-year | 20.73% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -6.00% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...